Radiopharm Theranostics (ASX:RAD) Full Year 2023 Results
Key Financial Results
Net loss: AU$34.6m (loss widened by 14% from FY 2022).
AU$0.11 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Radiopharm Theranostics Earnings Insights
Looking ahead, revenue is expected to decline by 150% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Australia are expected to grow by 9.2%.
The company's shares are up 4.4% from a week ago.
Don't forget that there may still be risks. For instance, we've identified 6 warning signs for Radiopharm Theranostics (2 are a bit unpleasant) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.